Batten-1 Phase 3 Study Initiation
Analysis based on 6 articles · First reported Jun 09, 2026 · Last updated Jun 09, 2026
The initiation of the international pivotal Phase 3 clinical study for Batten-1 by Theranexus>>> and Biocodex>>> is a significant positive development for the biotechnology and pharmaceutical sectors, particularly for companies focused on rare diseases. This advancement could lead to a new treatment for CLN3 Batten disease>>>, potentially boosting investor confidence in Theranexus>>> and similar companies, and opening new market opportunities for orphan drugs.
On International Batten Disease Awareness Day, THX Pharma (Theranexus), Biocodex>>>, and the Beyond Batten Disease Foundation>>> reaffirmed their commitment to patients affected by CLN3 Batten disease. They announced their joint Platinum Sponsorship of the 2026 BDSRA Annual Family Conference, where they will provide an update on the Batten-1 program. Batten-1 is an investigational miglustat-based therapy designed to slow the progression of CLN3 Batten disease. Building on positive Phase 1/2 results and real-world data, the partners are preparing to initiate an international pivotal Phase 3 clinical study in 2026. This study, funded by Biocodex>>> under a global licensing agreement, aims to support future Marketing Authorization Applications by 2029, with the goal of making Batten-1 widely available to patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard